Figure 1

Impact of recombinant erythropoietin on cisplatin-induced neurophysiological impairment. C57Bl/6 mice were repeatedly injected with cisplatin (2 mg/kg, i.p; 1×/week) or with cisplatin plus rhEPO (40 μg/kg, s.c.; 3×/week) or with rhEPO alone (40 μg/kg, sc; 3×/week) for 8 weeks. The control group was injected with saline alone (500 μl i.p.; 1×/week). Electrophysiological examinations of sensory nerve conduction velocity (SNCV) and motor nerve conduction velocity (MNCV) and the corresponding M- and H-amplitude were performed in week 9. Columns represent group (n = 10) mean values ± SEM. Differences were highly significant (p < 0.001; multiple t-test with Bonferroni corrections) for SNCV values of cisplatin vs. control, for cisplatin vs. cisplatin + rhEPO groups and for cisplatin vs. rhEPO and were marginally affected for MNCV values of cisplatin vs. control groups (p > 0.05). Differences between the corresponding M- or H-amplitudes of cisplatin vs. control, for cisplatin vs. cisplatin + rhEPO and cisplatin vs. rhEPO groups were significant as well (p < 0.05). All other differences for SNCV or MNCV values were not significant (p > 0.05). I: p < 0.001; II: p < 0.05.